<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">        <PMID Version="1">30405052</PMID>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>08</Day>        </DateRevised>        <Article PubModel="Electronic">            <Journal>                <ISSN IssnType="Print">2077-0383</ISSN>                <JournalIssue CitedMedium="Print">                    <Volume>7</Volume>                    <Issue>11</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Nov</Month>                        <Day>07</Day>                    </PubDate>                </JournalIssue>                <Title>Journal of clinical medicine</Title>                <ISOAbbreviation>J Clin Med</ISOAbbreviation>            </Journal>            <ArticleTitle>A DNA Methylation-Based Test for Breast Cancer Detection in Circulating Cell-Free DNA.</ArticleTitle>            <ELocationID EIdType="pii" ValidYN="Y">E420</ELocationID>            <ELocationID EIdType="doi" ValidYN="Y">10.3390/jcm7110420</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Breast cancer (BrC) is the most frequent neoplasm in women. New biomarkers, including aberrant DNA methylation, may improve BrC management. Herein, we evaluated the detection and prognostic performance of seven genes' promoter methylation (<i>APC</i>, <i>BRCA1</i>, <i>CCND2</i>, <i>FOXA1</i>, <i>PSAT1</i>, <i>RASSF1A</i> and <i>SCGB3A1</i>).</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">Methylation levels were assessed in primary BrC tissues by quantitative methylation-specific polymerase chain reaction (QMSP) and in circulating cell-free DNA (ccfDNA) by multiplex QMSP from two independent cohorts of patients (Cohort #1, <i>n</i> = 137; and Cohort #2, <i>n</i> = 44). Receiver operating characteristic (ROC) curves were constructed, and log-rank test and Cox regression were performed to assess the prognostic value of genes' methylation levels.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The gene-panel <i>APC</i>, <i>FOXA1</i>, <i>RASSF1A</i>, <i>SCGB3A1</i> discriminated normal from cancerous tissue with high accuracy (95.55%). In multivariable analysis, high <i>PSAT1</i>-methylation levels [&gt;percentile 75 (P75)] associated with longer disease-free survival, whereas higher <i>FOXA1</i>-methylation levels (&gt;P75) associated with shorter disease-specific survival. The best performing panel in ccfDNA (<i>APC</i>, <i>FOXA1</i> and <i>RASSF1A</i>) disclosed a sensitivity, specificity and accuracy over 70%.</AbstractText>                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This approach enables BrC accurate diagnosis and prognostic stratification in tissue samples, and allows for early detection in liquid biopsies, thus suggesting a putative value for patient management.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Salta</LastName>                    <ForeName>Sofia</ForeName>                    <Initials>S</Initials>                    <Identifier Source="ORCID">0000-0002-6707-1263</Identifier>                    <AffiliationInfo>                        <Affiliation>Cancer Biology &amp; Epigenetics Group-Research Center, Portuguese Oncology Institute of Porto (CI-IPOP), 4200-072 Porto, Portugal. sofia.salta@ipoporto.min-saude.pt.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Master in Oncology, Institute of Biomedical Sciences Abel Salazar-University of Porto (ICBAS-UP), 4050-313 Porto, Portugal. sofia.salta@ipoporto.min-saude.pt.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>P Nunes</LastName>                    <ForeName>Sandra</ForeName>                    <Initials>S</Initials>                    <Identifier Source="ORCID">0000-0003-4466-037X</Identifier>                    <AffiliationInfo>                        <Affiliation>Cancer Biology &amp; Epigenetics Group-Research Center, Portuguese Oncology Institute of Porto (CI-IPOP), 4200-072 Porto, Portugal. sandra22nunes@hotmail.com.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Master in Oncology, Institute of Biomedical Sciences Abel Salazar-University of Porto (ICBAS-UP), 4050-313 Porto, Portugal. sandra22nunes@hotmail.com.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Fontes-Sousa</LastName>                    <ForeName>Mário</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Breast Cancer Clinic and Department of Medical Oncology, Portuguese Oncology Institute of Porto, 4200-072 Porto, Portugal. mfontes.sousa@ipoporto.min-saude.pt.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Lopes</LastName>                    <ForeName>Paula</ForeName>                    <Initials>P</Initials>                    <AffiliationInfo>                        <Affiliation>Cancer Biology &amp; Epigenetics Group-Research Center, Portuguese Oncology Institute of Porto (CI-IPOP), 4200-072 Porto, Portugal. ana.ambrosio@ipoporto.min-saude.pt.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Pathology, Portuguese Oncology Institute of Porto, 4200-072 Porto, Portugal. ana.ambrosio@ipoporto.min-saude.pt.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Freitas</LastName>                    <ForeName>Micaela</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Cancer Biology &amp; Epigenetics Group-Research Center, Portuguese Oncology Institute of Porto (CI-IPOP), 4200-072 Porto, Portugal. micaelafariafreitas@gmail.com.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Caldas</LastName>                    <ForeName>Margarida</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Cancer Biology &amp; Epigenetics Group-Research Center, Portuguese Oncology Institute of Porto (CI-IPOP), 4200-072 Porto, Portugal. margaridabcaldas@yahoo.co.uk.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Pathology, Portuguese Oncology Institute of Porto, 4200-072 Porto, Portugal. margaridabcaldas@yahoo.co.uk.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Antunes</LastName>                    <ForeName>Luís</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Epidemiology, Portuguese Oncology Institute of Porto, 4200-072 Porto, Portugal. luis.antunes@ipoporto.min-saude.pt.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Castro</LastName>                    <ForeName>Fernando</ForeName>                    <Initials>F</Initials>                    <AffiliationInfo>                        <Affiliation>Breast Cancer Clinic and Department of Surgical Oncology, Portuguese Oncology Institute of Porto, 4200-072 Porto, Portugal. fcastro@ipoporto.min-saude.pt.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Antunes</LastName>                    <ForeName>Pedro</ForeName>                    <Initials>P</Initials>                    <AffiliationInfo>                        <Affiliation>Breast Cancer Clinic and Department of Surgical Oncology, Portuguese Oncology Institute of Porto, 4200-072 Porto, Portugal. pedrobiniantunes@gmail.com.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Palma de Sousa</LastName>                    <ForeName>Susana</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Breast Cancer Clinic and Department of Medical Oncology, Portuguese Oncology Institute of Porto, 4200-072 Porto, Portugal. susana.sousa@ipoporto.min-saude.pt.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Henrique</LastName>                    <ForeName>Rui</ForeName>                    <Initials>R</Initials>                    <Identifier Source="ORCID">0000-0003-3171-4666</Identifier>                    <AffiliationInfo>                        <Affiliation>Cancer Biology &amp; Epigenetics Group-Research Center, Portuguese Oncology Institute of Porto (CI-IPOP), 4200-072 Porto, Portugal. rmhenrique@icbas.up.pt.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Pathology, Portuguese Oncology Institute of Porto, 4200-072 Porto, Portugal. rmhenrique@icbas.up.pt.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar-University of Porto (ICBAS-UP), 4050-313 Porto, Portugal. rmhenrique@icbas.up.pt.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Jerónimo</LastName>                    <ForeName>Carmen</ForeName>                    <Initials>C</Initials>                    <Identifier Source="ORCID">0000-0003-4186-5345</Identifier>                    <AffiliationInfo>                        <Affiliation>Cancer Biology &amp; Epigenetics Group-Research Center, Portuguese Oncology Institute of Porto (CI-IPOP), 4200-072 Porto, Portugal. carmenjeronimo@ipoporto.min-saude.pt.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar-University of Porto (ICBAS-UP), 4050-313 Porto, Portugal. carmenjeronimo@ipoporto.min-saude.pt.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <GrantList CompleteYN="Y">                <Grant>                    <GrantID>PI 74-CI-IPOP-19-2016</GrantID>                    <Agency>Research Center of Portuguese Oncology Institute of Porto</Agency>                    <Country/>                </Grant>            </GrantList>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>11</Month>                <Day>07</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Switzerland</Country>            <MedlineTA>J Clin Med</MedlineTA>            <NlmUniqueID>101606588</NlmUniqueID>            <ISSNLinking>2077-0383</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Cell-free DNA</Keyword>            <Keyword MajorTopicYN="N">DNA methylation</Keyword>            <Keyword MajorTopicYN="N">breast cancer</Keyword>            <Keyword MajorTopicYN="N">diagnosis</Keyword>            <Keyword MajorTopicYN="N">epigenetic biomarker</Keyword>            <Keyword MajorTopicYN="N">liquid biopsy</Keyword>            <Keyword MajorTopicYN="N">prognosis</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>09</Month>                <Day>24</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>10</Month>                <Day>30</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>11</Month>                <Day>04</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>11</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>11</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>11</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>1</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30405052</ArticleId>            <ArticleId IdType="pii">jcm7110420</ArticleId>            <ArticleId IdType="doi">10.3390/jcm7110420</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>